Asbestos abatement violators go to trial, Orphan Drug Designation comes alive, Steve McQueen and Warren Zevon all take the stage at the Mesothelioma Center this week.
Related Post:
Drug Company Files for Orphan Drug Designation for Mesothelioma Treatment
Mesothelioma patients soon may have a new treatment option to consider for their rare and aggressive cancer. Pinnacle Biologics, Inc., an Illinois-based bio-pharmaceutical company, announced ...
Week in Review at the Mesothelioma Center: Alarming Asbestos News
The Week in Review at the Mesothelioma Center included helpful proposed legislation, an alarming report about asbestos imports, the small-cell lung cancer that killed the ...
Clinical Treatment CBP501 Receives FDA Orphan Drug Designation for Mesothelioma
CBP501, made by CanBas Co., is being tested as a treatment for mesothelioma. With the FDA's recent Orphan Drug Designation, the company can now receive ...
Week in Review: Asbestos Still Threatens Everyone Despite Reduction in Use
The Week in Review at the Mesothelioma Center touched on a variety of issues, including the continued threat posed by the toxic mineral.
Mesothelioma Treatment Phase II Clinical Trial Offers Hope
The biotechnology company MolMed, based in Italy, has announced positive results for their Phase II trial of NGR-hTNF for the treatment of malignant pleural mesothelioma. ...
Tags: abatement, Asbestos, asbestos cancer articles, Awareness, Clinical Trials, EPA, lawsuit, lung cancer, mesothelioma, mesothelioma and asbestos cancer, mesothelioma articles, mesothelioma cancer, treatment